胺碘酮治疗冠心病心房颤动的疗效和安全性观察  

Efficacy and Safety of Amiodarone in the Treatment of Atrial Fibrillation Patients with Coronary Heart Disease

作　　者：王云飞[1] 刘仁光[1] 姜凤伟[1] 

机构地区：[1]辽宁医学院附属第一医院,锦州市121001

出　　处：《中国药房》2011年第28期2632-2634,共3页China Pharmacy

摘　　要：目的:观察胺碘酮治疗冠心病心房颤动(以下简称房颤)的疗效和安全性。方法:将我院58例房颤患者纳为研究对象,男性38例,女性20例,其中阵发性房颤45例,持续性房颤13例。给予胺碘酮2周内负荷量为7 g,维持量为0.2 g.d-1。结果:随访0.3～6.8年,平均(3.5±1.5)年。显效42例(73.0%),有效8例(13.8%),总有效率为86.1%。其中,皮肤过敏3例(5.0%),四碘甲状腺原氨酸(T4)升高3例(5.1%),促甲状腺激素(TSH)降低2例(3.2%),TSH升高4例(6.9%),间质性肺病1例(1.7%),恶心、腹胀5例(8.6%),视力模糊3例(5.1%)。结论:胺碘酮治疗冠心病房颤疗效高、相对安全,但要注意早期发现及处理甲状腺和肺毒副作用。OBJECTIVE： To observe the efficacy and safety of amindarone in the treatment of atrial fibrillation （AF） patients with coronary heart disease. METHODS： 58 cases were included, involving 38 male and 20 female. There were 45 cases of parox- ysmal AF and 13 cases of persistent AF. Usage of amiodarone： a loading dose of 7 g were given within 2 weeks and the mainte- nance dose was 0.2 g·d^-1. RESULTS： Duration of following up was 0.3~6.8（3.5±1.5） years. 42 cases were significant effective （73.0%） and 8 cases were effective （13.8%）. The total effective rate was 86.1%. There were 3 cases of allergic reaction of skin （5.0 % ）. 3 cases of slight increase of T4 （5.1% ）, 2 cases of decrease of TSH （3.2 % ）, 4 cases of slight increase of TSH （6.9 % ）. i case of interstitial pulmonary disease （ 1.7 % ）, 5 cases of nausea or bloated feeling （8.6%） and 3 cases of blurred vision （5.1% ）. CONCLUSION： The treatment of amiodarone for AF patients with coronary heart disease is effective and relative safe. We should pay attention to the detection and treatment of thyroid and pulmonary toxicity at the early stage.

关 键 词：冠心病 心房颤动 胺碘酮 

分 类 号：R541.75[医药卫生—心血管疾病]